Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety of Sinutab on Subjects in the Setting of a Common Cold

This study has been completed.
Information provided by (Responsible Party):
Johnson & Johnson Consumer and Personal Products Worldwide ( McNeil AB ) Identifier:
First received: September 5, 2006
Last updated: July 6, 2012
Last verified: July 2012
The purpose of this study is to investigate the efficacy and safety for a marketed sinus allergy product, Sinutab, in the treatment of nasal congestion and headache.

Condition Intervention Phase
Common Cold
Nasal Congestion
Drug: Pseudoephedrine/Paracetamol
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Community Pharmacy Based Investigation in the Self-Medication Area Efficacy and Safety of Sinutab and Pseudoephedrine on Subjects With Nasal Congestion Accompanied by Headache in the Setting of a Common Cold

Resource links provided by NLM:

Further study details as provided by Johnson & Johnson Consumer and Personal Products Worldwide:

Primary Outcome Measures:
  • Change from baseline in the sum of nasal congestion and headache sign/symptom scores [ Time Frame: 7 days ]

Secondary Outcome Measures:
  • Change from baseline in the mean MSC score over the treatment days. The MSC score is defined as the sum of nasal congestion, headache, sore throat, and pressure around the eyes sign/symptom scores [ Time Frame: 7 days ]
  • Change from baseline in the mean individual sign/symptom score, including nasal congestion, headache, sore throat, and pressure around the eyes [ Time Frame: 7 days ]
  • Number of lost days at work or school [ Time Frame: 7 Days ]
  • Mean scores for: (a) interference with concentration; and (b) interference with sleep for days during treatment with study medication only [ Time Frame: 7 days ]
  • Safety evaluation by adverse event recording [ Time Frame: 7 days ]
  • Exploratory Endpoint: time to reach the first of two consecutive total Modified Jackson Subject Evaluation Scale (MJS) scores (defined as sum of 8 signs/symptoms) ≤ 1 [ Time Frame: Up to seven days ]

Enrollment: 469
Study Start Date: January 2007
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Pseudoephedrine/Paracetamol
Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime [Paracetamol (500 mg) and Pseudoephedrine (30 mg)]
Other Name: Sinutab

Detailed Description:

In response to a mandated requirement from the Belgium Medicines Agency - rising from the perforce switch of Sinutab® to a 2 active ingredients Pseudoephedrine+Paracetamol combination - we have made a commitment to demonstrate the safety and efficacy of Sinutab®.

In agreement with the Medicines Agency, an in-use Pharmacy-based study has been designed to demonstrate efficacy and safety of Sinutab® for the approved indications (symptomatic relief in the common cold).

This will be a randomized, double blind, placebo-controlled, comparative phase 4, multi-centre study in parallel groups between Sinutab and placebo. To study the drug in it's 'natural environment', community pharmacists will function as local investigators. Approximately 25 community pharmacists will be carefully selected, and only be taken into consideration if appropriate software programs are used in their pharmacy.

This implicates that the pharmacist has a medication record of his patients at his disposal which he will use to check the exclusion criteria. They will include subjects with early (≤ 48 hours) cold symptoms of blocked nose with headache. Subjects fulfilling the inclusion/exclusion criteria will be assigned to one of the two treatment groups, according to a computer-generated randomization list. A sufficient number of subjects will be randomized in the order of their enrolment, targeting at 300 evaluable subjects at the conclusion of study.

The following information will be collected every evening from subjects during 7 days: symptom assessment, compliance, adverse events and the ability to go to work or school.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18 years or more
  • reported cold symptoms beginning ≤ 48 hours prior to visit 1
  • scored ≥ 2 for each of nasal congestion and headache using the Modified Jackson Subject Evaluation Scale
  • willing and able to comply with scheduled visits, treatment plan, and other study procedures
  • evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial

Exclusion Criteria:

  • patients without an electronic medication record in the pharmacy
  • history of hypersensitivity to paracetamol or pseudoephedrine or lactose
  • fever more than 38.0°C (measured by pharmacist)
  • women in the fertile years who do not use a hormonal contraception or an intra-uterine device
  • use of concomitant drugs, medications or treatments that could interfere with the study drug
  • important intercurrent medical condition based on the available medication record of the patient. (cf. exclusion criterium 1)
  • history of nasal reconstructive surgery
  • alcohol and/or drug abuse within a 6-month period immediately preceding the screening visit
  • any medication or indication that might point to an increased risk, associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the study personnel, would make the subject inappropriate for inclusion
  • participation in other clinical trials the last three months and during study participation.
  • employees of the clinical research centers, sponsor, the CRO's contracted for this study, or their immediate family members
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00378144

JJCPPW Investigational Site
Wilrijk, Antwerp, Belgium
Sponsors and Collaborators
McNeil AB
Study Director: Elisabeth A Kruse, PhD JJCPPW
  More Information

Responsible Party: McNeil AB Identifier: NCT00378144     History of Changes
Other Study ID Numbers: A7801002
2006-000058-35 ( EudraCT Number )
Study First Received: September 5, 2006
Last Updated: July 6, 2012

Additional relevant MeSH terms:
Common Cold
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Nasal Decongestants
Vasoconstrictor Agents
Central Nervous System Stimulants
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Analgesics, Non-Narcotic
Sensory System Agents processed this record on April 27, 2017